514 related articles for article (PubMed ID: 17122008)
1. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
Halfon P; Trepo E; Antoniotti G; Bernot C; Cart-Lamy P; Khiri H; Thibaud D; Marron J; Martineau A; Pénaranda G; Benmoura D; Blanc B;
J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
[TBL] [Abstract][Full Text] [Related]
6. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
7. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
Li RZ; Shi JF; Zhou QZ; Wu RF; Li N; Wu LN; Zhou YQ; Wang Q; Liu ZH; Liu B; Qiao YL
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(5):307-11. PubMed ID: 16677522
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
10. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
[TBL] [Abstract][Full Text] [Related]
11. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
Baasland I; Romundstad PR; Eide ML; Jonassen CM
PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.
Belinson JL; Hu S; Niyazi M; Pretorius RG; Wang H; Wen C; Smith JS; Li J; Taddeo FJ; Burchette RJ; Qiao YL
Int J Cancer; 2010 Sep; 127(5):1151-7. PubMed ID: 20039323
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
15. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
16. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
19. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Liao SY; Rodgers WH; Kauderer J; Bonfiglio TA; Walker JL; Darcy KM; Carter R; Hatae M; Levine L; Spirtos NM; Stanbridge EJ
Int J Cancer; 2009 Nov; 125(10):2434-40. PubMed ID: 19670419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
